Clinical research of intercalated combination of osimertinib and docetaxel in T790M mutationpositive lung adenocarcinoma patients with bone metastasis in the southern Hainan Province

doi:10.3760/cma.j.issn.1673-422X.2019.07.002

Abstract

Abstract: ObjectiveTo study the clinical application of intercalated combination of osimertinib and docetaxel in T790M mutationpositive lung adenocarcinoma patients with bone metastasis in the southern Hainan Province. MethodsT790M mutationpositive lung adenocarcinoma patients with bone metastasis in the southern Hainan Province treated at the Third People′s Hospital of Hainan Province from January 2018 to October 2018 were enrolled, and they were divided into intercalated combination of osimertinib and docetaxel group (n=32) and osimertinib group (n=28) according to the treatment. The patients in intercalated combination of osimertinib and docetaxel group received oral osimertinib (80 mg, qd), and received docetaxel (75 mg/m2, repeated in threeweek intervals) when taking to tumor progression, and oral osimertinib treatment (80 mg, qd) was maintained until tumor partial response or stable disease after chemotherapy. The patients in osimertinib group received oral osimertinib (80 mg, qd). The patients in both groups received zoledronic acid. The response rate, disease control rate, overall survival (OS) and the incidence of adverse reactions of both groups were contrastively analyzed. ResultsThe response rate of intercalated combination of osimertinib and docetaxel group (62.5%, 20/32) was higher than that of osimertinib group (35.7%, 10/28), and disease control rate (93.8%, 30/32) was also higher than that of osimertinib group (67.9%, 19/28), with statistically significant differences (χ2=4.286, P=0.038; χ2=6.687, P=0.010). The median OS of intercalated combination of osimertinib and docetaxel group was 10.0 months, which was longer than that of osimertinib group (9.0 months), with statistically significant difference (χ2=5.917, P=0.015). Moreover, the adverse reactions in both groups were all grade Ⅰ or Ⅱ, which could be relieved or improved through symptomatic treatment. ConclusionIntercalated treatment of osimertinib with docetaxel is safe and effective in T790M mutationpositive lung adenocarcinoma patients with bone metastasis in the southern Hainan Province. It can prolong the survival time of patients.

Key words: Lung neoplasms, Osimertinib, Docetaxel, Bone metastasis, Southern Hainan Province

Chen Long, Lin Ling, Wang Cuiying, Wang Lin, He Donglei, Feng Jun. Clinical research of intercalated combination of osimertinib and docetaxel in T790M mutationpositive lung adenocarcinoma patients with bone metastasis in the southern Hainan Province[J]. Journal of International Oncology, 2019, 46(7): 399-403.

References

［1］ Cetin K, Christiansen CF, Jacobsen JB, et al. Bone metastasis, skeletalrelated events, and mortality in lung cancer patients: a Danish populationbased cohort study［J］. Lung Cancer, 2014, 86(2): 247254. DOI: 10.1016/j.lungcan.2014.08.022. ［2］ Reck M, Popat S, Reinmuth N, et al. Metastasis non small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up［J］. Ann Oncol, 2014, 25 Suppl 3: iii27iii39. DOI: 10.1093/annonc/mdu199. ［3］ Yashima H, Shimizu K, Araki T, et al. Assessment of DDR2, BRAF, EGFR and KRAS mutations as therapeutic targets in nonadenocarcinoma lung cancer patients［J］. Mol Clin Oncol, 2014, 2(5): 714718. DOI: 10.3892/mco.2014.302. ［4］中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会原发性肺癌诊疗指南（2018年版）［M］. 人民卫生出版社, 2018: 4950. ［5］ Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with nonsmall cell lung cancer［J］. J Clin Oncol, 2012, 30(4): 433440. DOI: 10.1200/JCO.2011.38.3224. ［6］刘曦光. 化疗与埃克替尼间插治疗在EGFR突变型非小细胞肺癌术后辅助治疗中的疗效与安全性［D］. 广州: 南方医科大学, 2016. ［7］王洁, 皮灿. 奥希替尼与培美曲塞联合铂类化疗在EGFRT790M阳性非小细胞肺癌患者中的疗效比较［J］. 循证医学, 2018, 18(1): 3639. ［8］ Wu YL, Lee JS, Thongprasert S, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage nonsmallcell lung cancer (FASTACT2): a randomized, double blind trial［J］. Lancet Oncl, 2013, 14(8): 777786. DOI: 10.1016/S14702045(13)702547. ［9］ Cheng Y, Murakami H, Yang PC, et al. Randomized phase Ⅱ trial of gefitinib with and without pemetrexed as firstline therapy in patients with advanced nonsquamous nonsmallcell lung cancer with activating epidermal growth factor receptor mutations［J］. J Clin Oncol, 2016, 34(27): 32583266. DOI: 10.1200/JCO.2016.66.9218. ［10］钱琳. 晚期非小细胞肺癌患者进行单药多西他赛二线治疗的临床研究［J］. 临床医药文献杂志, 2018, 15(5): 105106. ［11］ Jnne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR inhibitorresistant nonsmallcell lung cancer［J］. N Engl J Med, 2015, 372(18): 16891699. DOI: 10.1056/NEJMoa1411817. ［12］ Zhou T, Zeng SX, Ye DW, et al. A multicenter, randomized clinical trial comparing the threeweekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer［J］. PLoS One, 2015, 7: e0117002. DOI: 10.1371/journal.pone.0117002. ［13］胡林军，李长岭，寿建忠，等. 多西他赛治疗转移性去势抵抗性前列腺癌的耐受剂量及其与预后的关系［J］. 中华泌尿外科杂志, 2019, 40(1): 3136. DOI: 10.3760/cma.j.issn.10006702.2019.01.006.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	He Jiahui, Hu Qinyong. Comparative analysis of lung cancer incidence and mortality trends and risk factors in China and the United States based on GBD data [J]. Journal of International Oncology, 2024, 51(1): 29-36.
[3]	Ning Tingting, Hu Qinyong, Li Qian, Yang Pengcheng. Clinical efficacy of osimertinib and icotinib in first-line treatment of EGFR-positive metastatic NSCLC [J]. Journal of International Oncology, 2023, 50(2): 65-70.
[4]	Zuo Xiaoping, Liu Xiaochuan, Wu Xiqiang, Li Zhou, Xia Tian, Liu Guofeng. Risk factors and prediction model construction of arrhythmia in elderly patients with early lung cancer after thoracoscopic pulmonary resection [J]. Journal of International Oncology, 2023, 50(12): 711-716.
[5]	Chen Yu, Xu Hua, Liu Hai, Chen Shixin. Construction of pathological classification prediction model for malignant pulmonary pure ground-glass nodule patients based on CT imaging [J]. Journal of International Oncology, 2023, 50(11): 655-660.
[6]	Yang Sha, Yang Xiaohua, Wang Suhua, Xue Xiaoyan, Xu Jun. Analysis of risk factors for deep vein thrombosis of lower extremity after thoracoscopic surgery for elderly lung cancer and establishment and validation of prediction model [J]. Journal of International Oncology, 2022, 49(9): 532-536.
[7]	Chen Huangjing, Zhu Pengfei, Zhang Qing, Chen Guifang, Yang Chunlin, He Ying. Comparative study on the clinical value of contrast-enhanced ultrasound- and CT-guided percutaneous puncture biopsy in peripheral lung masses [J]. Journal of International Oncology, 2022, 49(8): 459-463.
[8]	Cai Gangxiang, Li Jing, Xu Bin. Advances in neoadjuvant immunotherapy for lung cancer [J]. Journal of International Oncology, 2022, 49(6): 366-370.
[9]	Zhang Jingxian, Yi Dan, Li Xiaojiang. Application of antibody-drug conjugates in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(5): 296-301.
[10]	Gao Min, Feng Jing, Wang Li, Zhong Hai, Wen Yuting, Wan Bing, Zhang Xiuwei. Application of microbiota in the early diagnosis and adjunctive treatment of lung cancer [J]. Journal of International Oncology, 2022, 49(4): 247-251.
[11]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu. Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(3): 140-145.
[12]	Xie Hongxia, Zuo Jinhui, Liao Dongying, Deng Renfen, Yao Yang, Jia Yingjie, Li Xiaojiang, Kong Fanming. Application of PD-L1 inhibitors in the treatment of non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(2): 111-115.
[13]	Geng Hui, Hu Fengchao, Lu Hongchao, Guo Jungang, Qi Zengping. Effects of TPF regimen and IMRT on immune function and survival prognosis of patients with advanced esophageal cancer [J]. Journal of International Oncology, 2022, 49(2): 84-88.
[14]	Huang Huayu, Song Qibin, Gong Hongyun, Song Jia. Analysis on the incidence and risk factors of pneumonia in patients with lung cancer receiving thoracic radiotherapy and immunotherapy [J]. Journal of International Oncology, 2022, 49(12): 718-723.
[15]	Zhang Hongjiao, Jiang Jie, Huang Wei. Research progress of functional imaging-assisted radiotherapy target delineation of lung cancer with atelectasis [J]. Journal of International Oncology, 2022, 49(1): 51-55.